Oculis Holding AG (OCS)
NASDAQ: OCS · IEX Real-Time Price · USD
11.78
-0.06 (-0.51%)
Apr 19, 2024, 4:30 PM EDT - Market closed
Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
The company is based in Zug, Switzerland.
Oculis Holding AG
| Country | Switzerland |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Dr. Riad Sherif M.B.A., M.D. |
Contact Details
Address: Bahnhofstrasse 7 Zug, V8 6300 Switzerland | |
| Phone | 617-937-2423 |
| Website | oculis.com |
Stock Details
| Ticker Symbol | OCS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001953530 |
| ISIN Number | CH1242303498 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Riad Sherif M.B.A., M.D. | Chief Executive Officer and Director |
| Sylvia Cheung | Chief Financial Officer |
| Weibo Ding | Global Chief Operating Officer and GM of China |
| Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer |
| Virginia R. Dean | Chief Human Resources Officer |
| Dr. Bastian Dehmel M.D. | Chief Development Officer |
| Páll Ragnar Jóhannesson | Chief Business Officer |
| Rebecca Weil | Chief Commercial Officer |
| Dr. Snehal Shah Pharm.D. | President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 424B5 | Filing |
| Apr 11, 2024 | 6-K | Report of foreign issuer |
| Apr 3, 2024 | EFFECT | Notice of Effectiveness |
| Apr 3, 2024 | 424B3 | Prospectus |
| Apr 2, 2024 | EFFECT | Notice of Effectiveness |
| Apr 1, 2024 | F-3 | Filing |
| Apr 1, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 19, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Feb 28, 2024 | 424B3 | Prospectus |